Pathogenesis of sarcoidosis

Presse Medicale

Volumn 41, Issue 6 PART 2, 2012, Pages

  Müller Quernheim, Joachim ^a   Prasse, Antje ^a   Zissel, Gernot ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GOLIMUMAB; INFLIXIMAB; TOLL LIKE RECEPTOR 2; USTEKINUMAB;

CYTOKINE RELEASE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR PATHOLOGY; SARCOIDOSIS; SHORT SURVEY;

EID: 84861920868     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.03.018     Document Type: Short Survey

References (166)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999, 160(2):736-755. American Thoracic Society.
2. Iannuzzi M.C., Iyengar S.K., Gray-McGuire C., Elston R.C., Baughman R.P., Donohue J.F., et al. Genome-wide search for sarcoidosis susceptibility genes in African Americans. Genes Immun 2005, 6(6):509-518.
3. Edmondstone W.M., Wilson A.G. Sarcoidosis in Caucasians, Blacks and Asians in London. Br J Dis Chest 1985, 79(1):27-36.
4. Rybicki B.A., Iannuzzi M.C., Frederick M.M., Thompson B.W., Rossman M.D., Bresnitz E.A., et al. Familial aggregation of sarcoidosis. A case control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001, 164(11):2085-2091.
5. Sverrild A., Backer V., Kyvik K.O., Kaprio J., Milman N., Svendsen C.B., et al. Heredity in sarcoidosis: a registry-based twin study. Thorax 2008, 63(10):894-896.
6. Iannuzzi M.C., Fontana J.R. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011, 305(4):391-399.
7. Baughman R.P., Culver D.A., Judson M.A. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011, 183(5):573-5781.
8. Teirstein A.S., Lesser M. Worldwide distribution and epidemiology of sarcoidosis. Sarcoidosis and other granulomatous diseases of the lung 1983, 101-134. Dekker, Basel. B. Fanburg (Ed.).
9. Hosoda Y., Yamaguchi M., Hiraga Y. Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us?. Clin Chest Med 1997, 18(4):681-694.
10. Byg K.E., Milman N., Hansen S. Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20(1):46-52.
11. Morimoto T., Azuma A., Abe S., Usuki J., Kudoh S., Sugisaki K., et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008, 31(2):372-379.
12. Anantham D., Ong S.J., Chuah K.L., Fook-Chong S., Hsu A., Eng P. Sarcoidosis in Singapore: epidemiology, clinical presentation and ethnic differences. Respirology 2007, 12(3):355-360.
13. Yigla M., Badarna-Abu-Ria N., Goralnik L., Rubin A.H., Weiler-Ravell D. Sarcoidosis in residents of northern Israel of Arabic and Jewish origin: a comparative study. Respirology 2006, 11(5):586-591.
14. Gribbin J., Hubbard R.B., Le Jeune I., Smith C.J., West J., Tata L.J. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006, 61(11):980-985.
15. Hagerstrand I., Linell F. The prevalence of sarcoidosis in the autopsie material of a swedish town. Acta Med Scan 1964, 425:171-173.
16. Reid J.D. Sarcoidosis in coroner's autopsies: a critical evaluation of diagnosis and prevalence from Cuyahoga County, Ohio. Sarcoidosis Vasc Diffuse Lung Dis 1998, 15(1):44-51.
17. Löfgren S. Primary pulmonary sarcoidosis. Acta Med Scand 1953, 145:424-465.
18. Grunewald J., Eklund A. Lofgren's syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009, 179(4):307-312.
19. Veien N.K. Cutaneous sarcoidosis: prognosis and treatment. Clin Dermatol 1986, 4:75-87.
20. Rossman M.D., Kreider M.E. Lesson learned from ACCESS (A Case Controlled Etiologic Study of Sarcoidosis). Proc Am Thorac Soc 2007, 4(5):453-456.
21. Rybicki B.A., Major M., Popovich J., Maliarik M.J., Iannuzzi M.C. Racial differences in sarcoidosis incidence: a 5-year study in health maintenance organization. Am J Epidemiol 1997, 145:234-241.
22. Vestbo J., Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis. Sarcoidosis 1994, 11:123-125.
23. Viskum K., Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J 1993, 6:349-353.
24. Swigris J.J., Olson A.L., Huie T.J., Fernandez-Perez E.R., Solomon J.J., Sprunger D., et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011, 140(5):1261-1266.
25. Baughman R.P., Lower E.E. Who dies from sarcoidosis and why?. Am J Respir Crit Care Med 2011, 183(11):1446-1447.
26. Nardi A., Brillet P.Y., Letoumelin P., Girard F., Brauner M., Uzunhan Y., et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011, 38(6):1368-1373.
27. Badrinas F., Morera J., Fité E., Plasencia A. Seasonal clustering of sarcoidosis. Lancet 1989, 334:455-456.
28. Kern D., Neill M., Wrenn D., Varone J. Investigation of a unique time-space cluster of sarcoidosis in firefighters. Am Rev Respir Dis 1993, 148:974-980.
29. Parkes S., Baker SdC, Bourdillon R., Murray C., Rakshit M. Epidemiology of sarcoidosis in the Isle of Man -1: a case controlled study. Thorax 1987, 42:420-426.
30. Edmondstone W. Sarcoidosis in nurses: is there an association?. Thorax 1988, 43:342-343.
31. Rafnsson V., Ingimarsson O., Hjalmarsson I., Gunnarsdottir H. Association between exposure to crystalline silica and risk of sarcoidosis. Occup Environ Med 1998, 55(10):657-660.
32. Kreider M.E., Christie J.D., Thompson B., Newman L., Rose C., Barnard J., et al. Relationship of environmental exposures to the clinical phenotype of sarcoidosis. Chest 2005, 128(1):207-215.
33. Burke W., Keogh A., Maloney P., Delprado W., Bryant D., Spratt P. Transmission of sarcoidosis via cardic transplantation. Lancet 1990, 336:1579.
34. Müller C., Briegel J., Haller M., Vogelmeier C., Bittman I., Welz A., et al. Sarcoidosis recurrence following lung transplantation. Transplantation 1996, 61(7):1117-1119.
35. Iqbal A., Aggarwal B., Menon B., Kulshreshtha R. Talc granulomatosis mimicking sarcoidosis. Singapore Med J 2008, 49(7):e168-e170.
36. Gysbrechts C., Michiels E., Verbeken E., Verschakelen J., Dinsdale D., Nemery B., et al. Interstitial lung disease more than 40 years after a 5-year occupational exposure to talc. Eur Respir J 1998, 11(6):1412-1415.
37. Drent M., Bomans P.H., Van Suylen R.J., Lamers R.J., Bast A., Wouters E.F. Association of man-made mineral fibre exposure and sarcoid-like granulomas. Respir Med 2000, 94(8):815-820.
38. Rybicki B.A., Amend K.L., Maliarik M.J., Iannuzzi M.C. Photocopier exposure and risk of sarcoidosis in African American sibs. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21(1):49-55.
39. Armbruster C., Dekan G., Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. Lancet 1996, 348:690.
40. Barnard J., Rose C., Newman L., Canner M., Martyny J., McCammon C., et al. Job and industry classifications associated with sarcoidosis in a case control etiologic study of sarcoidosis (ACCESS). J Occup Environ Med 2005, 47(3):226-234.
41. Newman L.S., Rose C.S., Bresnitz E.A., Rossman M.D., Barnard J., Frederick M., et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004, 170(12):1324-1330.
42. Gorham E.D., Garland C.F., Garland F.C., Kaiser K., Travis W.D., Centeno J.A. Trends and occupational associations in incidence of hospitalized pulmonary sarcoidosis and other lung diseases in Navy personnel: a 27-year historical prospective study, 1975-2001. Chest 2004, 126(5):1431-1438.
43. Kajdasz D.K., Lackland D.T., Mohr L.C., Judson M.A. A current assessment of rurally linked exposures as potential risk factors for sarcoidosis. Ann Epidemiol 2001, 11(2):111-117.
44. Sola R., Boj M., Hernandez-Flix S., Camprubi M. Silica in oral drugs as a possible sarcoidosis-inducing antigen. Lancet 2009, 373(9679):1943-1944.
45. Calvert G.M., Rice F.L., Boiano J.M., Sheehy J.W., Sanderson W.T. Occupational silica exposure and risk of various diseases: an analysis using death certificates from 27 states of the United States. Occup Environ Med 2003, 60(2):122-129.
46. Prezant D.J., Dhala A., Goldstein A., Janus D., Ortiz F., Aldrich T.K., et al. The incidence, prevalence, and severity of sarcoidosis in New York City firefighters. Chest 1999, 116(5):1183-1193.
47. Izbicki G., Chavko R., Banauch G.I., Weiden M.D., Berger K.I., Aldrich T.K., et al. World Trade Center "sarcoid-like" granulomatous pulmonary disease in New York City fire department rescue workers. Chest 2007, 131(5):1414-1423.
48. Crowley L.E., Herbert R., Moline J.M., Wallenstein S., Shukla G., Schechter C., et al. "Sarcoid-like" granulomatous pulmonary disease in World Trade Center disaster responders. Am J Ind Med 2011, 54(3):175-184.
49. Miller A. Sarcoidosis, firefighters sarcoidosis, and World Trade Center "sarcoid-like" granulomatous pulmonary disease. Chest 2007, 132(6):2053.
50. Jordan H.T., Stellman S.D., Prezant D., Teirstein A., Osahan S.S., Cone J.E. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. J Occup Environ Med 2011, 53(9):966-974.
51. Rose C.S., Martyny J.W., Newman L.S., Milton D.K., King T.E., Beebe J.L., et al. "Lifeguard lung": endemic granulomatous pneumonitis in an indoor swimming pool. Am J Public Health 1998, 88(12):1795-1800.
52. Demirkok S.S., Basaranoglu M., Akbilgic O. Seasonal variation of the onset of presentations in stage 1 sarcoidosis. Int J Clin Pract 2006, 60(11):1443-1450.
53. Kajdasz D.K., Judson M.A., Mohr L.C., Lackland D.T. Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators. Am J Epidemiol 1999, 150(3):271-278.
54. Müller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998, 12(3):716-738.
55. Iannuzzi M.C., Rybicki B.A., Teirstein A.S. Sarcoidosis. N Engl J Med 2007, 357(21):2153-2165.
56. Berlin M., Fogdell-Hahn A., Olerup O., Eklund A., Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997, 156(5):1601-1605.
57. Maná J., Gomez-Vaquero C., Montero A., Salazar A., Marcoval J., Valverde J., et al. Löfgren's syndrome revisited: a study of 186 patients. Am J Med 1999, 107(3):240-245.
58. Müller-Quernheim J., Gaede K.I., Fireman E., Zissel G. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur Respir J 2006, 27:1190-1195.
59. McGrath D.S., Goh N., Foley P.J., du Bois R.M. Sarcoidosis: genes and microbes: soil or seed?. Sarcoidosis Vasc Diffuse Lung Dis 2001, 18(2):149-164.
60. Fite E., Alsina J.M., Anto J.M., Morera J. Sarcoidosis: family contact study. Respiration 1998, 65(1):34-39.
61. Rybicki B.A., Harrington D., Major M., Simoff M., Popovich J., Maliarik M., et al. Heterogeneity of familial risk in sarcoidosis. Genet Epidemiol 1996, 13(1):23-33.
62. Schürmann M., Reichel P., Müller-Myhsok B., Schlaak M., Müller-Quernheim J., Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med 2001, 164(5):840-846.
63. Rybicki B.A., Sinha R., Iyengar S., Gray-McGuire C., Elston R.C., Iannuzzi M.C. Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study. Genes Immun 2007, 8(5):379-386.
64. Fischer A., Nothnagel M., Schürmann M., Müller-Quernheim J., Schreiber S., Hofmann S. A genome-wide linkage analysis in 181 German sarcoidosis families using clustered bi-allelic markers. Chest 2010, 138(1):151-157.
65. Valentonyte R., Hampe J., Huse K., Rosenstiel P., Albrecht M., Stenzel A., et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005, 37(4):357-364.
66. Franke A., Fischer A., Nothnagel M., Becker C., Grabe N., Till A., et al. Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2. Gastroenterology 2008, 135(4):1207-1215.
67. Hofmann S., Franke A., Fischer A., Jacobs G., Nothnagel M., Gaede K.I., et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008, 40(9):1103-1106.
68. Hofmann S., Fischer A., Till A., Muller-Quernheim J., Hasler R., Franke A., et al. A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1. Eur Respir J 2011, 38(5):1127-1135.
69. Rybicki B.A., Hirst K., Iyengar S.K., Barnard J.G., Judson M.A., Rose C.S., et al. A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasc Diffuse Lung Dis. 2005, 22(2):115-122.
70. Judson M.A., Hirst K., Iyengar S.K., Rybicki B.A., El-Ghormli L., Baughman R.P., et al. Comparison of sarcoidosis phenotypes among affected African American siblings. Chest 2006, 130(3):855-862.
71. Valentonyte R., Hampe J., Croucher P.J., Müller-Quernheim J., Schwinger E., Schreiber S., et al. Study of C-C chemokine receptor 2 alleles in sarcoidosis, with emphasis on family-based analysis. Am J Respir Crit Care Med 2005, 171(10):1136-1141.
72. Design of a case control etiologic study of sarcoidosis (ACCESS). J Clin Epidemiol 1999, 52(12):1173-1186. ACCESS research group.
73. Bogunia-Kubik K., Tomeczko J., Suchnicki K., Lange A. HLA-DRB1*03, DRB1*11 or DRB1*12 and their respective DRB3 specificities in clinical variants of sarcoidosis. Tissue Antigens 2001, 57(1):87-90.
74. Grubic Z., Zunec R., Peros-Golubicic T., Tekavec-Trkanjec J., Martinez N., Alilovic M., et al. HLA class I and class II frequencies in patients with sarcoidosis from Croatia: role of HLA-B8, -DRB1*0301, and -DQB1*0201 haplotype in clinical variations of the disease. Tissue Antigens 2007, 70(4):301-306.
75. Mrazek F., Holla L.I., Hutyrova B., Znojil V., Vasku A., Kolek V., et al. Association of tumour necrosis factor-alpha, lymphotoxin-alpha and HLA-DRB1 gene polymorphisms with Lofgren's syndrome in Czech patients with sarcoidosis. Tissue Antigens 2005, 65(2):163-171.
76. Wennerstrom A., Pietinalho A., Vauhkonen H., Lahtela L., Palikhe A., Hedman J., et al. HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis. Hum Immunol 2012, 73(1):93-100.
77. Grunewald J., Eklund A., Olerup O. Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med 2004, 169(6):696-702.
78. Sato H., Grutters J.C., Pantelidis P., Mizzon A.N., Ahmad T., Van Houte A.J., et al. HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002, 27(4):406-412.
79. Voorter C.E., Drent M., van den Berg-Loonen E.M. Severe pulmonary sarcoidosis is strongly associated with the haplotype HLA-DQB1*0602-DRB1*150101. Hum Immunol 2005, 66(7):826-835.
80. Voorter C.E., Drent M., Hoitsma E., Faber K.G., van den Berg-Loonen E.M. Association of HLA-DQB1 0602 in sarcoidosis patients with small fiber neuropathy. Sarcoidosis Vasc Diffuse Lung Dis 2005, 22(2):129-132.
81. Sato H., Nagai S., du Bois R.M., Handa T., Suginoshita Y., Ohta K., et al. HLA-DQB1 0602 allele is associated with splenomegaly in Japanese sarcoidosis. J Intern Med 2007, 262(4):449-457.
82. Grunewald J., Olerup O., Persson U., Ohrn M.B., Wigzell H., Eklund A. T-cell receptor variable region gene usage by CD4+ and CD8+ T-cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci U S A 1994, 91(11):4965-4969.
83. Grunewald J., Eklund A. Sex-specific manifestations of Löfgren's syndrome. Am J Respir Crit Care Med 2007, 175(1):40-44.
84. Voorter C.E., Amicosante M., Berretta F., Groeneveld L., Drent M., van den Berg-Loonen E.M. HLA class II amino acid epitopes as susceptibility markers of sarcoidosis. Tissue Antigens 2007, 70(1):18-27.
85. Foley P.J., McGrath D.S., Puscinska E., Petrek M., Kolek V., Drabek J., et al. Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis. Am J Respir Cell Mol Biol 2001, 25(3):272-277.
86. Wahlstrom J., Dengjel J., Persson B., Duyar H., Rammensee H.G., Stevanovic S., et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest 2007, 117(11):3576-3582.
87. Li Y., Wollnik B., Pabst S., Lennarz M., Rohmann E., Gillissen A., et al. BTNL2 gene variant and sarcoidosis. Thorax 2006, 61(3):273-274.
88. Rybicki B.A., Walewski J.L., Maliarik M.J., Kian H., Iannuzzi M.C. The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet 2005, 77(3):491-499.
89. Arnett H.A., Escobar S.S., Gonzalez-Suarez E., Budelsky A.L., Steffen L.A., Boiani N., et al. BTNL2, a butyrophilin/B7-like molecule, is a negative co-stimulatory molecule modulated in intestinal inflammation. J Immunol 2007, 178(3):1523-1533.
90. Zissel G., Homolka J., Schlaak J., Schlaak M., Müller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996, 154:713-719.
91. Grutters J.C., Sato H., Pantelidis P., Lagan A.L., McGrath D.S., Lammers J.W., et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002, 165(8):1119-1124.
92. Seitzer U., Swider C., Stüber F., Suchnicki K., Lange A., Richter E., et al. Tumour necrosis factor-alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997, 9(10):787-790.
93. Somoskövi A., Zissel G., Seitzer U., Gerdes J., Schlaak M., Müller-Quernheim J. Polymorphism at position -308 in the promotor region of the TNF-alpha and in the first intron o the TNF-beta genes and spontaneous and lipopolysaccharide-induced TNF-alpha release in sarcoidosis. Cytokine 1999, 11(11):882-887.
94. Swider C., Schnittger L., Bogunia-Kubik K., Gerdes J., Flad H., Lange A., et al. TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. Eur Cytokine Netw 1999, 10(2):143-146.
95. Seitzer U., Gerdes J., Müller-Quernheim J. Evidence for disease phenotype associated haplotypes (DR.TNF) in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001, 18(3):279-283.
96. Takashige N., Naruse T.K., Matsumori A., Hara M., Nagai S., Morimoto S., et al. Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens 1999, 54(2):191-193.
97. Medica I., Kastrin A., Maver A., Peterlin B. Role of genetic polymorphisms in ACE and TNF-alpha gene in sarcoidosis: a meta-analysis. J Hum Genet 2007, 52(10):836-847.
98. Petrek M., Drabek J., Kolek V., Zlamal J., Welsh K.I., Bunce M., et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000, 162(3 Pt 1):1000-1003.
99. Takada T., Suzuki E., Ishida T., Moriyama H., Ooi H., Hasegawa T., et al. Polymorphism in RANTES chemokine promoter affects extent of sarcoidosis in a Japanese population. Tissue Antigens 2001, 58(5):293-298.
100. Takada T., Suzuki E., Morohashi K., Omori K., Gejyo F. MCP-1 and MIP-1A gene polymorphisms in Japanese patients with sarcoidosis. Intern Med 2002, 41(10):813-818.
101. Spagnolo P., Renzoni E.A., Wells A.U., Copley S.J., Desai S.R., Sato H., et al. C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. Am J Respir Crit Care Med 2005, 172(6):721-728.
102. Spagnolo P., Renzoni E.A., Wells A.U., Sato H., Grutters J.C., Sestini P., et al. C-C chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome. Am J Respir Crit Care Med 2003, 168(10):1162-1166.
103. Hizawa N., Yamaguchi E., Furuya K., Jinushi E., Ito A., Kawakami Y. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med 1999, 159(6):2021-2023.
104. Fischer A., Valentonyte R., Nebel A., Nothnagel M., Müller-Quernheim J., Schürmann M., et al. Female-specific association of C-C chemokine receptor 5 gene polymorphisms with Lofgren's syndrome. J Mol Med 2008, 86(5):553-561.
105. Chen E.S., Song Z., Willett M.H., Heine S., Yung R.C., Liu M.C., et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010, 181(4):360-373.
106. Veltkamp M., van Moorsel C.H., Rijkers G.T., Ruven H.J., Grutters J.C. Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) influences disease course in sarcoidosis. Tissue Antigens 2011, 79(1):25-32.
107. Pabst S., Baumgarten G., Stremmel A., Lennarz M., Knufermann P., Gillissen A., et al. Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clin Exp Immunol 2006, 143(3):420-426.
108. Sato M., Kawagoe T., Meguro A., Ota M., Katsuyama Y., Ishihara M., et al. Toll-like receptor 2 (TLR2) gene polymorphisms are not associated with sarcoidosis in the Japanese population. Mol Vis 2011, 17:731-736.
109. Schurmann M., Kwiatkowski R., Albrecht M., Fischer A., Hampe J., Muller-Quernheim J., et al. Study of Toll-like receptor gene loci in sarcoidosis. Clin Exp Immunol 2008, 152(3):423-431.
110. Wiken M., Grunewald J., Eklund A., Wahlstrom J. Higher monocyte expression of TLR2 and TLR4, and enhanced pro-inflammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis. J Clin Immunol 2009, 29(1):78-89.
111. Rastogi R., Du W., Ju D., Pirockinaite G., Liu Y., Nunez G., et al. Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am J Respir Crit Care Med 2011, 183(4):500-510.
112. Veltkamp M., Van Moorsel C.H., Rijkers G.T., Ruven H.J., Van Den Bosch J.M., Grutters J.C. Toll-like receptor (TLR)-9 genetics and function in sarcoidosis. Clin Exp Immunol 2010, 162(1):68-74.
113. Hattori T., Konno S., Takahashi A., Isada A., Shimizu K., Shimizu K., et al. Genetic variants in mannose receptor gene (MRC1) confer susceptibility to increased risk of sarcoidosis. BMC Med Genet 2010, 11:151.
114. Gilbert S., Steinbrech D.S., Landas S.K., Hunninghake G.W. Amounts of angiotensin converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am Rev Respir Dis 1993, 148:483-486.
115. Biller H., Zissel G., Ruprecht B., Nauck M., Busse Grawitz A., Muller-Quernheim J. Genotype-corrected reference values for serum angiotensin converting enzyme. Eur Respir J 2006, 28(6):1085-1090.
116. Kruit A., Grutters J.C., Gerritsen W.B., Kos S., Wodzig W.K., van den Bosch J.M., et al. ACE I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir Med 2007, 101(3):510-515.
117. Kruit A., Ruven H.J., Grutters J.C., van den Bosch J.M. Angiotensin II receptor type 1 1166 A/C and angiotensin converting enzyme I/D gene polymorphisms in a Dutch sarcoidosis cohort. Sarcoidosis Vasc Diffuse Lung Dis 2010, 27(2):147-152.
118. Fatimathas L., Moss S.E. Characterisation of the sarcoidosis associated variant of annexin A11. Gen Physiol Biophys 2009, 28 Spec No Focus:F29-F38.
119. Li Y., Pabst S., Kubisch C., Grohe C., Wollnik B. First independent replication study confirms the strong genetic association of ANXA11 with sarcoidosis. Thorax 2010, 65(10):939-940.
120. Mrazek F., Stahelova A., Kriegova E., Fillerova R., Zurkova M., Kolek V., et al. Functional variant ANXA11 R230C: true marker of protection and candidate disease modifier in sarcoidosis. Genes Immun 2011, 12(6):490-494.
121. Koth L.L., Solberg O.D., Peng J.C., Bhakta N.R., Nguyen C.P., Woodruff P.G. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 2011, 184(10):1153-1163.
122. Hirschhorn J.N. Genome-wide association studies--illuminating biologic pathways. N Engl J Med 2009, 360(17):1699-1701.
123. Hunter D.J., Altshuler D., Rader D.J. From Darwin's finches to canaries in the coal mine--mining the genome for new biology. N Engl J Med 2008, 358(26):2760-2763.
124. Kraft P., Hunter D.J. Genetic risk prediction--are we there yet?. N Engl J Med 2009, 360(17):1701-1703.
125. Zissel G., Prasse A., Muller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med 2010, 31(4):390-403.
126. El-Zammar O.A., Katzenstein A.L. Pathological diagnosis of granulomatous lung disease: a review. Histopathology 2007, 50(3):289-310.
127. Rosen Y. Pathology of sarcoidosis. Semin Respir Crit Care Med 2007, 28(1):36-52.
128. Müller-Quernheim J., Saltini C., Sondermeyer P., Crystal R.G. Compartmentalized activation of the interleukin-2 gene by lung T-lymphocytes in active pulmonary sarcoidosis. J Immunol 1986, 137:3475-3483.
129. Grunewald J., Wahlstrom J., Berlin M., Wigzell H., Eklund A., Olerup O. Lung restricted T-cell receptor AV2S3+ CD4+ T-cell expansions in sarcoidosis patients with a shared HLA-DRbeta chain conformation. Thorax 2002, 57(4):348-352.
130. Strausz J., Männel D.N., Pfeifer S., Borkowski A., Ferlinz R., Müller-Quernheim J. Spontaneous monokine release by alveolar macrophages in chronic sarcoidosis. Int Arch Allergy Appl Immunol 1991, 96(1):68-75.
131. Ziegenhagen M.W., Benner U.K., Zissel G., Zabel P., Schlaak M., Müller-Quernheim J., et al. TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997, 156(5):1586-1592.
132. Ziegenhagen M.W., Rothe M.E., Zissel G., Muller-Quernheim J. Exaggerated TNF-alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19(3):185-190.
133. Du Bois R.M., Kirby M., Balbi B., Saltini C., Crystal R.G. T-lymphocytes that accumulate in the lung in sarcoidosis have evidence of recent stimulation of the T-cell antigen receptor. Am Rev Respir Dis 1992, 145(5):1205-1211.
134. Silver R.F., Crystal R.G., Moller D.R. Limited heterogeneity of biased T-cell receptor V beta gene usage in lung but not blood T-cells in active pulmonary sarcoidosis. Immunology 1996, 88(4):516-523.
135. Zissel G., Bäumer I., Fleischer B., Schlaak M., Müller-Quernheim J. TCR V beta families in T-cell clones from sarcoid lung parenchyma, BAL, and blood. Am J Respir Crit Care Med 1997, 156(5):1593-1600.
136. Pabst R., Schuster M., Tschernig T. Lymphocyte dynamics in the pulmonary microenvironment: implications for the pathophysiology of pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999, 16(2):197-202.
137. Petzmann S., Maercker C., Markert E., Kern I., Osolnik K., Pohl W., et al. Enhanced proliferation and decreased apoptosis in lung lavage cells of sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23(3):190-200.
138. Sugiyama K., Mukae H., Ishii H., Kakugawa T., Ishimoto H., Nakayama S., et al. Elevated levels of interferon gamma-inducible protein-10 and epithelial neutrophil-activating peptide-78 in patients with pulmonary sarcoidosis. Respirology 2006, 11(6):708-714.
139. Pignatti P., Brunetti G., Moretto D., Yacoub M.R., Fiori M., Balbi B., et al. Role of the chemokine receptors CXCR3 and CCR4 in human pulmonary fibrosis. Am J Respir Crit Care Med 2006, 173(3):310-317.
140. Planck A., Katchar K., Eklund A., Gripenback S., Grunewald J. T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20(2):110-117.
141. Prasse A., Zissel G., Lutzen N., Schupp J., Schmiedlin R., Gonzalez-Rey E., et al. Inhaled Vasoactive Intestinal Peptide Exerts Immuno-regulatory Effects in Sarcoidosis. Am J Respir Crit Care Med 2010, 182(4):540-548.
142. Idali F., Wahlstrom J., Muller-Suur C., Eklund A., Grunewald J. Analysis of regulatory T-cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis. Clin Exp Immunol 2008, 152(1):127-137.
143. Rappl G., Pabst S., Riemann D., Schmidt A., Wickenhauser C., Schutte W., et al. Regulatory T-cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol 2011, 140(1):71-83.
144. Taflin C., Miyara M., Nochy D., Valeyre D., Naccache J.M., Altare F., et al. FoxP3+ regulatory T-cells suppress early stages of granuloma formation but have little impact on sarcoidosis lesions. Am J Pathol 2009, 174(2):497-508.
145. McGeachy M.J., Chen Y., Tato C.M., Laurence A., Joyce-Shaikh B., Blumenschein W.M., et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T-helper cells in vivo. Nat Immunol 2009, 10(3):314-324.
146. Facco M., Cabrelle A., Teramo A., Olivieri V., Gnoato M., Teolato S., et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011, 66(2):144-150.
147. Fischer A., Nothnagel M., Franke A., Jacobs G., Saadati H.R., Gaede K.I., et al. Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. Eur Respir J 2011, 37(3):610-616.
148. Richter E., Greinert U., Kirsten D., Rusch-Gerdes S., Schluter C., Duchrow M., et al. Assessment of mycobacterial DNA in cells and tissues of mycobacterial and sarcoid lesions. Am J Respir Crit Care Med 1996, 153(1):375-380.
149. Planck A., Eklund A., Grunewald J., Vene S. No serological evidence of Rickettsia helvetica infection in Scandinavian sarcoidosis patients. Eur Respir J 2004, 24(5):811-813.
150. Martens H., Zöllner B., Zissel G., Burdon D., Schlaak M., Müller-Quernheim J. Anti-Borrelia burgdorferi immunoglobulin seroprevalence in pulmonary sarcoidosis. Eur Respir J 1997, 10:1356-1358.
151. James D.G., Williams W.J. Kveim-Siltzbach test revisited. Sarcoidosis 1991, 8:6-9.
152. Richter E., Kataria Y.P., Zissel G., Homolka J., Schlaak M., Muller-Quernheim J. Analysis of the Kveim-Siltzbach test reagent for bacterial DNA. Am J Respir Crit Care Med 1999, 159(6):1981-1984.
153. Song Z., Marzilli L., Greenlee B.M., Chen E.S., Silver R.F., Askin F.B., et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005, 201(5):755-767.
154. Chen E.S., Wahlstrom J., Song Z., Willett M.H., Wiken M., Yung R.C., et al. T-cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008, 181(12):8784-8796.
155. Oswald-Richter K., Sato H., Hajizadeh R., Shepherd B.E., Sidney J., Sette A., et al. Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T-cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101. J Clin Immunol 2010, 30(1):157-166.
156. Homma J.Y., Abe C., Chosa H., Ueda K., Saegusa J., Nakayama M., et al. Bacteriological investigation on biopsy specimens from patients with sarcoidosis. Jpn J Exp Med 1978, 48(3):251-255.
157. Ishige I., Usui Y., Takemura T., Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 1999, 354(9173):120-123.
158. Chen E.S., Moller D.R. Sarcoidosis--scientific progress and clinical challenges. Nat Rev Rheumatol 2011, 7(8):457-467.
159. Ziegenhagen M.W., Rothe M.E., Schlaak M., Muller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003, 21(3):407-413.
160. Sweiss N.J., Salloum R., Gandhi S., Alegre M.L., Sawaqed R., Badaracco M., et al. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS One 2010, 5(2):e9088.
161. Miyara M., Amoura Z., Parizot C., Badoual C., Dorgham K., Trad S., et al. The immune paradox of sarcoidosis and regulatory T-cells. J Exp Med 2006, 203(2):359-370.
162. Prasse A., Katic C., Germann M., Buchwald A., Zissel G., Muller-Quernheim J. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 2008, 177(3):330-336.
163. Müller-Quernheim J., Pfeifer S., Strausz J., Ferlinz R. Correlation of clinical and immunological parameters of the inflammatory activity of pulmonary sarcoidosis. Am Rev Respir Dis 1991, 144:1322-1329.
164. Park M.K., Fontana, Babaali H., Gilbert-McClain L.I., Stylianou M., Joo J., et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26(2):121-131.
165. Moller D.R., Wysocka M., Greenlee B.M., Ma X., Wahl L., Karp C.L. Inhibition of human interleukin-12 production by pentoxifylline. Immunology 1997, 91:197-203.
166. Baughman R.P., Drent M., Kavuru M., Judson M.A., Costabel U., du Bois R., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174(7):795-802.